Gabby Lopez

Gabby Lopez

Auto-generated profile, based on publicly available information

Gabby Lopez

SWOG Statistics and Data Management Center, Seattle, WA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2017 in Scandinavian Journal of Medicine & Science in Sports
Verified
Journal Article
Open access
PDF file
GLG. A. Lopez
G. A. Lopez
ABAttn: Jan Christian Brønd
Attn: Jan Christian Brønd
LALars Bo Andersen
Lars Bo Andersen
OBOla Björgell
Ola Björgell
DADaniel Arvidsson
Daniel Arvidsson
SenseWear Armband (SW) is a multisensor monitor to assess physical activity and energy expenditure. Its prediction algorithms have been updated periodically. The aim was to validate SW in children, adolescents, and adults. The most recent SW algorithm 5.2 (SW5.2) and the previous version 2.2 (SW2.2) were evaluated for estimation of energy expenditure during semi‐structured activities in 35 children, 31 adolescents, and 36 adults with indirect calorimetry as reference. Energy expenditure estimated from waist‐worn ActiGraph GT3X+ data (AG) was used for comparison. Improvements in measurement errors were demonstrated with SW5.2 compared to SW2.2, especially in children and for biking. The overall mean absolute percent error with SW5.2 was 24% in children, 23% in adolescents, and 20% in adults. The error was larger for sitting and standing (23%‐32%) and for basketball and biking (19%‐35%), compared to walking and running (8%‐20%). The overall mean absolute error with AG was 28% in children, 22% in adolescents, and 28% in adults. The absolute percent error for biking was 32%‐74% with AG. In general, SW and AG underestimated energy expenditure. However, both methods demonstrated a proportional bias, with increasing underestimation for increasing energy expenditure level, in addition to the large individual error. SW provides measures of energy expenditure level with similar accuracy in children, adolescents, and adults with the improvements in the updated algorithms. Although SW captures biking better than AG, these methods share remaining measurements errors requiring further improvements for accurate measures of physical activity and energy expenditure in clinical and epidemiological research.

26 October 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSandip Pravin Patel
Sandip Pravin Patel
MOMegan Othus
Megan Othus
YCYoung Kwang Chae
Young Kwang Chae
MDMichael J. Dennis
Michael J. Dennis
SGSarah Gordon
Sarah Gordon
RKRazelle Kurzrock
Razelle Kurzrock
Purpose: The efficacy of immune checkpoint blockade in gestational trophoblastic neoplasia (GTN) remains uncertain. We report the results of the GTN cohort of SWOG S1609 dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART). Patients and Methods: This prospective, open-label phase II trial evaluated ipilimumab plus nivolumab across multiple rare tumor cohorts, including GTN. Eligible patients received nivolumab 240 mg, i.v. every 2 weeks and ipilimumab 1 mg/kg i.v. every 6 weeks. The primary endpoint was overall response rate [ORR; complete response (CR) + partial response (PR)] by quantitative serum beta human chorionic gonadotropin (β-hCG); secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. Results: Four patients with refractory GTN enrolled and received therapy. At 11 months of ongoing follow-up, 3 of 4 patients responded [ORR = 75% (CR, 25%, n = 1, tumor mutation burden = 1 mutation/megabase; PD-L1 tumor proportion score = 50%); PR, 50%, n = 2)]. Responders included malignant gestational trophoblastic neoplasm (n = 1, CR, PFS 11+ months) and choriocarcinoma (n = 2, both PRs, PFS 10+ and 6+ months). One patient with epithelioid trophoblastic tumor experienced disease progression. The 6-month PFS was 75% [95% confidence interval (CI), 43%–100%], and the median PFS was not reached (range, 35–339+ days); all 4 patients were alive at last follow-up. Two patients experienced grade 3 immune-related toxicity (arthralgia and colitis); there were no grade ≥4 events. Conclusions: Ipilimumab plus nivolumab demonstrated efficacy in chemotherapy-refractory GTN, an ultra-rare cancer affecting young women. Three of 4 patients achieved ongoing objective responses with a reasonable safety profile at 6–11+ months.

15 February 2024 in Cancer
Verified
Journal Article
Closed access
SPSandip Pravin Patel
Sandip Pravin Patel
EGElizabeth Guadarrama
Elizabeth Guadarrama
YCYoung Kwang Chae
Young Kwang Chae
MDMichael J. Dennis
Michael J. Dennis
BPBenjamin C. Powers
Benjamin C. Powers
RKRazelle Kurzrock
Razelle Kurzrock

17 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YCYoung Kwang Chae
Young Kwang Chae
MOMegan Othus
Megan Othus
SPSandip Pravin Patel
Sandip Pravin Patel
KWKelly J. Wilkinson
Kelly J. Wilkinson
EWEmily M. Whitman-Purves
Emily M. Whitman-Purves
RKRazelle Kurzrock
Razelle Kurzrock
Purpose: The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be explored. Patients and Methods: Dual anti–CTLA-4 and anti–PD-1 blockade in rare tumor is a prospective, multicenter (1,016 US sites), multicohort, single-arm phase II trial conducted through the Early Therapeutics and Rare Cancer SWOG/NCI Committee, assessing ipilimumab (anti–CTLA-4; 1 mg/kg every 6 weeks) and nivolumab (anti–PD-1; 240 mg every 2 weeks) in adults with advanced nonepithelial ovarian cancers who lack beneficial standard therapy. The primary outcome was overall response rate [ORR; complete response (CR)/partial response (PR)]; secondary outcomes were progression-free survival (PFS), overall survival, clinical benefit rate [stable disease (SD) ≥6 months plus ORR], and toxicity. Results: Seventeen patients (median age: 64; number of prior therapies ranged from 0 to 8 with no immunotherapy exposure; eight granulosa, six carcinosarcomas, one Sertoli–Leydig, one yolk sac, and one Wolffian) were evaluated. In granulosa cell tumors, ORR was 25% (n = 2/8; one CR and one PR) and clinical benefit rate was 50% (n = 4/8); PFS was 58.3 (CR), 50.7+ (PR), 30.4 (SD), and 8.7 (SD) months. Median PFS was 3.5 months [95% confidence interval, 1.7–11.2 months]; median overall survival was 42.5 months (95% confidence interval, 10.1 months–not reached). One Sertoli–Leydig cell tumor showed a 22% regression (PFS, 11.2 months). Carcinosarcomas had no response. Three participants (18%) discontinued treatment due to grade 3 to grade 4 adverse events. Conclusions: Ipilimumab–nivolumab shows activity in treatment-refractory granulosa cell tumors, with 25% (n = 2/8) of patients experiencing either CR or PR lasting more than 4 years.

1 October 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MHMarium Husain
Marium Husain
MXMenglin Xu
Menglin Xu
SPS. Patel
S. Patel
AJA. Johns
A. Johns
MGM. Grogan
M. Grogan
DOD. Owen
D. Owen